Integrated Investment Consultants LLC Grows Stock Position in Johnson & Johnson (NYSE:JNJ)

Integrated Investment Consultants LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 72,382 shares of the company's stock after purchasing an additional 7,070 shares during the period. Johnson & Johnson accounts for about 0.2% of Integrated Investment Consultants LLC's holdings, making the stock its 24th biggest position. Integrated Investment Consultants LLC's holdings in Johnson & Johnson were worth $10,468,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Spring Capital Management LLC raised its stake in shares of Johnson & Johnson by 11.7% during the 4th quarter. Spring Capital Management LLC now owns 44,932 shares of the company's stock worth $6,498,000 after purchasing an additional 4,691 shares during the period. Dominguez Wealth Management Solutions Inc. raised its position in Johnson & Johnson by 1.1% in the fourth quarter. Dominguez Wealth Management Solutions Inc. now owns 23,707 shares of the company's stock worth $3,429,000 after acquiring an additional 261 shares during the period. Canoe Financial LP grew its position in shares of Johnson & Johnson by 3.2% during the 4th quarter. Canoe Financial LP now owns 92,626 shares of the company's stock valued at $13,396,000 after acquiring an additional 2,900 shares during the period. Retirement Wealth Solutions LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $73,000. Finally, Brooklyn Investment Group raised its holdings in shares of Johnson & Johnson by 33.2% in the 4th quarter. Brooklyn Investment Group now owns 16,457 shares of the company's stock worth $2,380,000 after purchasing an additional 4,099 shares during the period. 69.55% of the stock is owned by institutional investors.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the business's stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on JNJ shares. Morgan Stanley boosted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 16th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. StockNews.com downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday. Bank of America dropped their price target on shares of Johnson & Johnson from $166.00 to $160.00 and set a "neutral" rating on the stock in a research note on Friday. Finally, Royal Bank of Canada lifted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a research note on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $174.29.

Johnson & Johnson Price Performance

JNJ traded down $0.74 on Monday, reaching $147.03. The company had a trading volume of 10,678,393 shares, compared to its average volume of 6,880,262. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a market cap of $353.99 billion, a price-to-earnings ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The business has a 50 day simple moving average of $148.51 and a 200 day simple moving average of $156.10.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.37%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is currently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.